Call or Text Us Today 314-697-4867

Call or Text Us Today 314-697-4867

Clinical Research: TMS for Autism Spectrum Disorder

Transcranial Magnetic
Stimulation (TMS)

Transcranial Magnetic Stimulation (TMS) is gaining momentum as a non-invasive, drug-free option for supporting individuals with autism spectrum disorder (ASD). At Palmier TMS, we believe in transparency and informed care, which is why we’ve compiled the latest clinical research for families and patients seeking answers.

Below, you'll find highlights from key clinical trials, systematic reviews, and expert insights that illustrate the growing body of evidence supporting TMS as a viable intervention for autism symptoms.

🔬 2024 Systematic Review: 17 Studies (2018–2023)

A comprehensive 2024 meta-analysis reviewed 17 peer-reviewed studies exploring TMS in children and adults with ASD. These included both randomized controlled trials (RCTs) and open-label studies.

The Key Findings

  • Behavioral Improvements: Notable reductions in stereotyped and repetitive behaviors along with enhancements in social communication as measured by standardized ASD rating scales.
  • Brain Function Changes: EEG and neuroimaging showed increased connectivity and normalized activity in autism-related brain regions.
  • Protocol Variety: Researchers used both repetitive TMS (rTMS) and intermittent Theta Burst Stimulation (iTBS) with treatment durations ranging from 1 to 18 weeks and session frequency of 1 to 5 times per week.
  • EEG-Guided TMS (MeRT): The review emphasized that EEG-guided targeting, like the approach used at Palmier TMS, may enhance treatment precision and outcomes.

“TMS has positive effects on stereotypical behavior, repetitive behavior, verbal and social aspects of ASD, leading to overall improvement across all scale scores post-intervention.”

— TMS Institute Research Summary

đź§Ş Large Multisite Randomized Controlled Trial (2024)

As the largest TMS study for autism to date, this multisite RCT investigates a 4-week course of iTBS targeting the right temporoparietal junction (rTPJ)—a brain region central to social cognition.

MRI-guided Neuronavigation

Conducted with MRI-guided neuronavigation and comprehensive neuropsychological evaluations

Biomedical Treatment

Aims to assess whether TMS can become the first biomedical treatment specifically for social communication deficits in ASD

High Potential

Results are pending, but early indicators suggest high potential for this protocol’s use in clinical practice

📍 Yale Medicine Trial

  • Connect with leads with zero hassle.
  • Take quick payments direct from meetings
  • Start finding leads that get coverts quickly

📍 Deep rTMS Study (BrainsWay)

  • Aimed at improving social relating by stimulating the dorsomedial prefrontal cortex
  • Early-stage data indicate potential benefits, though specific results have yet to be published.

đź’¬ What the
Experts Are Saying

Leading researchers in neuroscience have voiced optimism about TMS for ASD:

Dr. Manuel Casanova

A renowned autism researcher, notes that TMS has been linked to gains in cognitive function and better behavioral outcomes in ASD.

2016 review

A landmark 2016 review already suggested TMS as a "transformative" approach—one that’s now being validated by current, larger-scale studies.

📊 Summary Table of Key Research

Study / Review

Design & Scope

Main Takeaways

2024 Systematic Review [1,2,3]

Multisite RCT (2024) [4]

Yale Trial [5]

Deep rTMS Trial [6]

17 studies, including RCTs and open-label trials

Largest ongoing study using iTBS

Double-blind, randomized

Targeted to dorsomedial prefrontal cortex

Reductions in repetitive behaviors; improvements in social communication and neuroconnectivity

Aims to establish TMS as a biomedical treatment for social deficits

Uses EEG/eye-tracking to measure TMS effectiveness on social brain areas

Focused on social relating; results pending

Study / Review

Design & Scope

Main Takeaways

2024 Systematic Review [1,2,3]

Multisite RCT (2024) [4]

Yale Trial [5]

Deep rTMS Trial [6]

17 studies, including RCTs and open-label trials

Largest ongoing study using iTBS

Double-blind, randomized

Targeted to dorsomedial prefrontal cortex

Reductions in repetitive behaviors; improvements in social communication and neuroconnectivity

Aims to establish TMS as a biomedical treatment for social deficits

Uses EEG/eye-tracking to measure TMS effectiveness on social brain areas

Focused on social relating; results pending

📌 Conclusion: Is TMS a
Breakthrough for Autism?

The most encouraging data to date suggest that TMS—especially when guided by EEG and tailored to the individual brain—can lead to meaningful improvements in ASD symptoms. These include enhanced social communication, fewer repetitive behaviors, and better emotional regulation. Results are further supported by neuroimaging and electrophysiological changes that reflect real shifts in brain function.

While TMS is not yet FDA-approved for autism, clinical use is growing as more providers—including Palmier TMS—adopt evidence-based protocols supported by science. Additional large-scale studies are in progress, and the momentum behind this treatment continues to build.